Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's DiseaseRandall J. Bateman, John C. Morris, Virginia Buckles et al.|New England Journal of Medicine|2012Cited by 3.8k
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s diseaseStephen Salloway, Paul Aisen, Martin R. Farlow et al.|Nature Medicine|2021Cited by 365
The DIAN‐TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression modelRandall J. Bateman, Chengjie Xiong, Tammie L.S. Benzinger et al.|Alzheimer s & Dementia|2016Cited by 303
Preclinical trials in autosomal dominant AD: Implementation of the DIAN-TU trialSusan Mills, Randall J. Bateman, J. Mallmann et al.|Revue Neurologique|2013Cited by 136
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trialRandall J. Bateman, Bruno Dubois, Yan Li et al.|The Lancet Neurology|2025Cited by 39